Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652601 | 0.85 | CYP2D6 (0.79) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL1164461 | 0.82 | CYP2D6 (0.74) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL5512457 | 0.81 | CYP2D6 (0.68) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL23052533 | 0.81 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 | |
| SCHEMBL28588864 | 0.81 | CYP2D6 (0.72) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL5200239 | 0.80 | CYP2C9 (0.66) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL26242973 | 0.80 | CYP2D6 (0.66) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL15009831 | 0.80 | CYP2C9 (0.66) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL15018169 | 0.80 | CYP2D6 (0.66) | CYP2D6CYP2C9CYP2C19TSHRHPGD | |
| SCHEMBL27601052 | 0.80 | CYP2D6 (0.70) | CYP2D6CYP2C9CYP2C19TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119447465-A | Electrolyte and application thereof in double-ion battery | 广西师范大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119447465-A | Electrolyte and application thereof in double-ion battery | 广西师范大学 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023061051-A1 | SULFAMIDE USP8 INHIBITOR AND USE THEREOF | 中国药科大学 | 2023-04-20 | — | — | WO | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7687459-B2 | Arylalkoxyl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7511063-B2 | High affinity quinoline-based kinase ligands | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-12-25 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | SCHERING CORPORATION | 2008-02-21 | — | — | US | disclosed |
| US-7084170-B2 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045568-A1 | Novel high affinity quinoline-based kinase ligands | CDKL2, CDK2, CDKL1 | CYP2D6 3846/4885CYP2C9 4575/4885CYP2C19 4055/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | CYP2D6 386/4885CYP2C9 452/4885CYP2C19 444/4885 |
| US-20080317712-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PREP, DNPEP, CTSC | CYP2D6 381/4885CYP2C9 312/4885CYP2C19 227/4885 |
| US-20090098085-A1 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | CYP2D6 615/4885CYP2C9 300/4885CYP2C19 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.